With many treatments for #PsA and #PsO, what are the prescribing trends? Abstract 0604: TNF inhibitors remain the most
Tweet Content
With many treatments for #PsA and #PsO, what are the prescribing trends?
Abstract 0604: TNF inhibitors remain the most common (~60%), but over the past 10 years, IL-17i use rose from 0.2% to 19%, and IL-23i from 0.1% to 39.7%! #ACR24 @RheumNow https://t.co/4TnCAkHfuY
Show on Archive Page
On
Display in Search Results
On
PDQ
Off